Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Why Kirk Spano sees Pfizer as one of the next big winners from AI and why he thinks investors should be selling cash secured ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...